Harry CB, Liu W, Ma, Vera E, Andrews WH, Briggs La, Raphael JM. Research on Rejuvenation. February 2011; 14（1）：45—56.

Background

This one-year human study showed that taking TA-65 capsules improved telomere length and immune system biomarkers in individuals. This study confirms the health effects previously mentioned by TA-65 and identifies other areas of overall health support that require further research. The study also observed the in vitro effects of TA-65 on cultured human cells.

Research Model

114 study participants underwent testing for telomere length and other biomarkers of aging process before and one year after TA-65 administration, with checkpoints at baseline and 3, 6, 9, and 12 months. The subjects take 5 to 10 milligrams of TA-65 daily. The monitored health areas include: blood cell count, immune system status and function, cytomegalovirus status, kidney health, liver health, endocrine function, cholesterol balance, serum nutritional status, glucose metabolism, inflammatory response, cardiovascular health, bone mineral density, skin health, vision and mental acuity, and total telomere length. The study subjects did not report any adverse events. This study also explored the in vitro effects of TA-65 using cultured human neonatal keratinocytes and fetal fibroblasts.

Survey results and action methods

Multiple in vitro experiments have confirmed that TA-65 supports enhanced telomerase activation in human cells. It is worth noting that two to three times the upregulation effect was observed at very low doses. Meanwhile, untreated and carrier only (DMSO) treated cells showed very weak telomerase activity.

Survey results, health impact

To investigate the immune system effects of TA-65, the CMV status of all participants was recorded at the beginning of the study. The CMV+state is common and can be considered a common aspect of the aging process. The positive rate of telomerase activation in this group is relatively low (54%), and the average age is 63 years old, so the research group allows for the isolation of the effects of age and cytomegalovirus status on immune cell health.

The most important finding of this one-year study is clear support for:

Reduced percentage of short telomeres

Healthy number of neutrophils in CMV+subjects

Reduce the percentage of non functional aging cytotoxic T cells

The overall distribution map of "younger" immune cells

Survey results, safety

No adverse events were found, and there were no reports of uncontrolled cell growth during the study period. Some participants increased their dosage to 25 or 50 milligrams per day without any side effects.